Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
346 questions in 59 reviews · Vascular
current versionsNo studies 346 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clopidogrel vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Sulphinpyrazone vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Sulphinpyrazone vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or arteriovenous graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Glyceryl trinitrate patch vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Glyceryl trinitrate patch vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Ticlopidine vs placebo Duration of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Ticlopidine vs placebo Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts (2021) · Cochrane | no estimate extracted | NR | No studies |
Cilostazol vs pentoxifylline Arterial revascularisation · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | no estimate extracted | NR | No studies |
Cilostazol vs pentoxifylline Amputation · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | no estimate extracted | NR | No studies |
Cilostazol vs pentoxifylline Cardiovascular event · intermittent claudication Cilostazol for intermittent claudication (2021) · Cochrane | no estimate extracted | NR | No studies |
Radiofrequency ablation (RFA) vs mechanochemical ablation (MOCA) Technical success (> 5 years) · people with GSV incompetence Interventions for great saphenous vein incompetence (2021) · Cochrane | no estimate extracted | NR | No studies |
Radiofrequency ablation (RFA) vs mechanochemical ablation (MOCA) Long‐term recurrence (≥ 5 years) · people with GSV incompetence Interventions for great saphenous vein incompetence (2021) · Cochrane | no estimate extracted | NR | No studies |
Alpha blockers vs placebo QoL · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Alpha blockers vs placebo RCS · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Prostagladin/prostacyclin analogues vs placebo Duration of attacks · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Prostagladin/prostacyclin analogues vs placebo QoL · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Prostagladin/prostacyclin analogues vs placebo RCS · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Thromboxane synthase inhibitors vs placebo Severity of attacks · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Thromboxane synthase inhibitors vs placebo Duration of attacks · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Thromboxane synthase inhibitors vs placebo QoL · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Thromboxane synthase inhibitors vs placebo Adverse events · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Thromboxane synthase inhibitors vs placebo RCS · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Selective serotonin reuptake inhibitors vs placebo QoL · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Selective serotonin reuptake inhibitors vs placebo RCS · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Nitrate/nitrate derivatives vs placebo QoL · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs placebo QoL · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Phosphodiesterase inhibitors vs placebo QoL · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Angiotensin‐converting enzyme inhibitors vs placebo RCS · primary Raynaud's phenomenon Vasodilators for primary Raynaud's phenomenon (2021) · Cochrane | no estimate extracted | NR | No studies |
Compression stockings vs compression stockings Quality of life · people with varicose veins without venous ulceration Graduated compression stockings for the initial treatment of varicose veins in people without venous… (2021) · Cochrane | no estimate extracted | NR | No studies |
Propionyl‐L‐carnitine vs L‐carnitine Progression of disease (to Fontaine stage III or IV or necessity for intervention (endovascular or surgery)) · people with intermittent claudication Propionyl‐L‐carnitine for intermittent claudication (2021) · Cochrane | no estimate extracted | NR | No studies |
Propionyl‐L‐carnitine vs L‐carnitine Side effects of propionyl‐L‐carnitine regimen · people with intermittent claudication Propionyl‐L‐carnitine for intermittent claudication (2021) · Cochrane | no estimate extracted | NR | No studies |
Propionyl‐L‐carnitine vs L‐carnitine Ankle brachial index · people with intermittent claudication Propionyl‐L‐carnitine for intermittent claudication (2021) · Cochrane | no estimate extracted | NR | No studies |
Propionyl‐L‐carnitine vs L‐carnitine Quality of life · people with intermittent claudication Propionyl‐L‐carnitine for intermittent claudication (2021) · Cochrane | no estimate extracted | NR | No studies |
Extensive tests vs tests at the physician's discretion All‐cause mortality1 · people with unprovoked VTE Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in… (2021) · Cochrane | no estimate extracted | NR | No studies |
Standard testing plus PET/CT scanning vs standard testing alone VTE‐related mortality4 · people with unprovoked VTE Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in… (2021) · Cochrane | no estimate extracted | NR | No studies |
Extensive tests vs tests at the physician's discretion VTE‐related mortality4 · people with unprovoked VTE Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in… (2021) · Cochrane | no estimate extracted | NR | No studies |
Extensive tests vs tests at the physician's discretion VTE‐related morbidity5 · people with unprovoked VTE Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in… (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant) Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (STS) vs sclerotherapy (any sclerosant) Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (STS) vs sclerotherapy (any sclerosant) Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (STS) vs sclerotherapy (any sclerosant) Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant) Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) Recurrence · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) Time to resolution · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |
Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant) Quality of life · people with telangiectasias and reticular veins Treatment for telangiectasias and reticular veins (2021) · Cochrane | no estimate extracted | NR | No studies |